Parkinson’s Disease
Parkinson’s Disease is a disorder of the central nervous system that affects movement, often including tremors.
Nerve cell damage in the brain causes dopamine levels to drop, leading to the symptoms of Parkinson’s.
Parkinson’s often starts with a tremor in one hand. Other symptoms are slow movement, stiffness, and loss of balance.
Medications can help control the symptoms of Parkinson’s.
Parkinson’s Disease is a progressive disease of the nervous system marked by tremor, muscular rigidity, and slow, imprecise movement, chiefly affecting middle-aged and elderly people. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine.
Symptoms:
Cluster Number:
Wiki Number: PW153
Diagnosis: Parkinson’s Disease (Very complex; please read the Wikipedia article.)
US Patients: 2-6X likelihood of dementia
World Patients: 6.2Mil&117,400 Deaths (2015)
Sex Ratio:
Age Onset: Over 60, usually; unless “early-onset Parkinson’s”
Brain Area: Cell deaths among the subantia nigra leads to dopamine deficits; Cells die from proteins into Lewy bodies in the neurons
Symptoms: tremor, slowness(bradykinesia), stiffness(excessive muscle contraction) and postural instability(10% fall weekly)
Progression: As it progresses, poor decision-making, less impulse control, impaired recall, less control of attention
Causes: genetics, injuries, pesticides;brain lesions from strokes;alpha-synuclein protein in the brain buildup; 50% have hallucinations
Medications: L-DOPA; deep brain stimulation by microelectrodes reduces muscular symptoms;
Therapies: Imaging by MRI, T2* and SW;, neuromelanin-MRI; Diffusion, MRI; PET; SPECT; DaTSCAN is the only FDA approved way to distinguish.
Youtube Video: Parkinson’s Disease: Adversity or Adventure?
Amazon or Library Book:
Parkinson’s Disease – Guide for the Newly Diagnosed
Click the book to link or buy from Amazon.
Support Group: parkinsons.org; 800-473-4636
(Parkinson’s Disease Foundation)
Support Group:michaeljfox.org; (Primarily designed to find a cure for Parkinson’s Disease. It may also have support groups.)
Contact your local Social Security office for possible Disability Benefits through their Disability Determination Services,
Section 12.02.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Tailoring and personalizing deep brain stimulation for Parkinson's diseaseby Rubens Gisbert Cury on May 19, 2024
No abstract
- Graphene acid quantum dots: A highly active multifunctional carbon nano material that intervene in the trajectory towards neurodegenerationby Sherin M ElMorsy on May 19, 2024
Carbon dots (CDs) are carbon nano materials (CNMs) that find use across several biological applications because of their water solubility, biocompatible nature, eco-friendliness, and ease of synthesis. Additionally, their physiochemical properties can be chemically tuned for further optimization towards specific applications. Here, we investigate the efficacy of C70-derived Graphene Acid Quantum Dots (GAQDs) in mitigating the transformation of soluble, monomeric Hen Egg-White Lysozyme (HEWL) to...
- Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trialby Chris C Parker on May 19, 2024
BACKGROUND: Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain.
- Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trialby Chris C Parker on May 19, 2024
BACKGROUND: Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear.